About Medizone International

Medizone International, Inc. Corporate History

 

Medizone International (OTCBB:MZEI) (OTCQB:MZEI) was originally organized in New York City in 1986 to develop treatments for a family of viruses known as lipid enveloped. Diseases such as Hepatitis B and C, HIV/AIDS, Herpes and Epstein Barr are included in this family of common viruses.

In 2007 the United States Center for Disease Control (CDC) declared hospital acquired infections (HAI) a ‘silent epidemic.’ Approximately 100,000 people a year die in the United States every year from these largely preventable hospital acquired infections. One person every 5 minutes. The media has expressed it as the equivalent of a 747 with 288 people on board going down every single day. HAI is considered the fourth leading cause of death in the United States. It is a global problem. In 2008 we decided that we could do something about that and shifted the focus of the company to the development of our hospital disinfection system.

Medizone has successfully achieved patents for this technology, which we have labeled AsepticSure Market introduction began in Canada and will next be introduced into the United States. There is a global market for this product as AsepticSure provides a solution to a previously unsolvable problem.

Prior to AsepticSure, disinfection systems and best cleaning practices could not routinely break what we refer to as ‘the sick room syndrome.’ In a health care setting, a sick room is a room that continues to demonstrate a higher incident of HAI associated with it than adjoining rooms in the facility. A significant part of the cause for this is that infective- bacteria has become part of the room, and previous cleaning practices simply could not eradicate it. Cleaning would reduce it, but then it grows back.

AsepticSure is now demonstrating the ability to kill 100% of the bacteria in a problem room. No other technology has demonstrated this capability. When you kill 100% of the bacteria in a space, evidence suggests the room will remain infection free until a new source of bacteria is introduced.

On the other hand, our research demonstrates that if you leave even .1% of bacteria, ie: you kill 99.9% and leave .1% – that small amount of remaining bacteria will grow back to full strength in about 5 days. We believe this is why hospitals have continuing reinfection issues for the causative agents of HAI despite best conventional cleaning practices.

AsepticSure is demonstrating the capability of eliminating 100% of these bacteria inside of patient rooms, ORs and other critical infrastructure spaces. It does so while all content, including medical equipment, remains in the room.

The following is a list of the bacteria proven to be fully eliminated by AsepticSure at our Innovation Park, Queens University Laboratories.

 

  • Clostridium difficile (C. difficile)
  • Escherichia coli (E. coli)
  • Pseudomonas aeruginosa
  • Methicillin-resistant Staphylococcus aureus (MRAS)
  • Vancomycin-resistant Enterococcus (VRE)
  • Salmonella
  • Listeria
  • Bacillius subtilis
  • Mycobacterium terrae (surrogate for Mycobacterium tuberculosis)
  • Klebsiella pneumonia

 

In our opinion there is not a known causative agent of HAI that AsepticSure cannot achieve 100% kill with. Our laboratories are not rated for viruses, thus we have not worked with viruses during the AsepticSure program. However, given our long history of working with viruses and ozone prior to the AsepticSure program, our scientists are very sure that the elimination of viruses in the health care setting should not present a challenge for AsepticSure.

Contact:

Medizone International, Inc. (MZEI.OB)

4000 Bridgeway, Suite 401
Sausalito, CA 94965

Telephone: 415-331-0303

Email: operations@medizoneint.com

Investor Relations:

John Pentony

Investor Relations
Medizone International, Inc.

Telephone: (415) 331-0202

E: j.pentony@medizoneint.com

Media Contact:

Gary Hanauer

Media Relations
Medizone International, Inc.

Telephone: (510) 686-1238

E: GarHan@aol.com